Reevaluating the safety of shortened antibiotic treatment: a critical evaluation of the EUROBACT-2 study. Authors' reply.

No abstract available

COI Statement

Conlict of interet: None related to this reply.

References:

Pruc M, Maslyk M, Krupa A et al (2025) Reevaluating the safety of shortened antibiotic treatment: a critical evaluation of the EUROBACT-2 study. Intensive Care Med. https://doi.org/10.1007/s00134-025-07919-9
Gajdos L, Buetti N, Tabah A, Ruckly S, Akova M, Sjoval F, Arvanti K, de Waele J, Bracht H, Barbier F, Timsit JF (2025) Shortening antibiotic therapy duration for hospital-acquired bloodstream infections in critically ill patients: a causal inference model from the international EUROBACT-2 database. Intensive Care Med. https://doi.org/10.1007/s00134-025-07857-6
Balance Investigators ftCCCTGtAoMM, Infectious Disease Canada Clinical Research Network tA, New Zealand Intensive Care Society Clinical Trials G, the Australasian Society for Infectious Diseases Clinical Research N, Daneman N, Rishu A, Pinto R, Rogers BA, Shehabi Y, Parke R, Cook D, Arabi Y, Muscedere J, Reynolds S, Hall R, Dwivedi DB, Mcarthur C, McGuinness S, Yahav D, Coburn B, Geagea A, Das P, Shin P, Detsky M, Morris A, Fralick M, Powis JE, Kandel C, Sligl W, Bagshaw SM, Singhal N, Belley-Cote E, Whitlock R, Khwaja K, Morpeth S, Kazemi A, Williams A, MacFadden DR, McIntyre L, Tsang J, Lamontagne F, Carignan A, Marshall J, Friedrich JO, Cirone R, Downing M, Graham C, Davis J, Duan E, Neary J, Evans G, Alraddadi B, Al Johani S, Martin C, Elsayed S, Ball I, Lauzier F, Turgeon A, Stelfox HT, Conly J, McDonald EG, Lee TC, Sullivan R, Grant J, Kagan I, Young P, Lawrence C, O’Callaghan K, Eustace M, Choong K, Aslanian P, Buehner U, Havey T, Binnie A, Prazak J, Reeve B, Litton E, Lother S, Kumar A, Zarychanski R, Hoffman T, Paterson D, Daley P, Commons RJ, Charbonney E, Naud JF, Roberts S, Tiruvoipati R, Gupta S, Wood G, Shum O, Miyakis S, Dodek P, Kwok C, Fowler RA, Infectious Disease Canada Clinical Research Network tA, New Zealand Intensive Care Society Clinical Trials G, the Australasian Society for Infectious Diseases Clinical Research N (2025) Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. N Engl J Med 392:1065–1078
Zhou Z, Rahme E, Abrahamowicz M, Pilote L (2005) Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 162:1016–1023

Article info

Journal issue:

Volume: not provided
Issue: not provided

Doi:

10.1007/s00134-025-07927-9

More resources:

Springer

Full Text Sources

Paid

Reevaluating the safety of shortened antibiotic treatment: a critical evaluation of the EUROBACT-2 study. Authors' reply.

No abstract available

COI Statement

Conlict of interet: None related to this reply.

References:

Pruc M, Maslyk M, Krupa A et al (2025) Reevaluating the safety of shortened antibiotic treatment: a critical evaluation of the EUROBACT-2 study. Intensive Care Med. https://doi.org/10.1007/s00134-025-07919-9
Gajdos L, Buetti N, Tabah A, Ruckly S, Akova M, Sjoval F, Arvanti K, de Waele J, Bracht H, Barbier F, Timsit JF (2025) Shortening antibiotic therapy duration for hospital-acquired bloodstream infections in critically ill patients: a causal inference model from the international EUROBACT-2 database. Intensive Care Med. https://doi.org/10.1007/s00134-025-07857-6
Balance Investigators ftCCCTGtAoMM, Infectious Disease Canada Clinical Research Network tA, New Zealand Intensive Care Society Clinical Trials G, the Australasian Society for Infectious Diseases Clinical Research N, Daneman N, Rishu A, Pinto R, Rogers BA, Shehabi Y, Parke R, Cook D, Arabi Y, Muscedere J, Reynolds S, Hall R, Dwivedi DB, Mcarthur C, McGuinness S, Yahav D, Coburn B, Geagea A, Das P, Shin P, Detsky M, Morris A, Fralick M, Powis JE, Kandel C, Sligl W, Bagshaw SM, Singhal N, Belley-Cote E, Whitlock R, Khwaja K, Morpeth S, Kazemi A, Williams A, MacFadden DR, McIntyre L, Tsang J, Lamontagne F, Carignan A, Marshall J, Friedrich JO, Cirone R, Downing M, Graham C, Davis J, Duan E, Neary J, Evans G, Alraddadi B, Al Johani S, Martin C, Elsayed S, Ball I, Lauzier F, Turgeon A, Stelfox HT, Conly J, McDonald EG, Lee TC, Sullivan R, Grant J, Kagan I, Young P, Lawrence C, O’Callaghan K, Eustace M, Choong K, Aslanian P, Buehner U, Havey T, Binnie A, Prazak J, Reeve B, Litton E, Lother S, Kumar A, Zarychanski R, Hoffman T, Paterson D, Daley P, Commons RJ, Charbonney E, Naud JF, Roberts S, Tiruvoipati R, Gupta S, Wood G, Shum O, Miyakis S, Dodek P, Kwok C, Fowler RA, Infectious Disease Canada Clinical Research Network tA, New Zealand Intensive Care Society Clinical Trials G, the Australasian Society for Infectious Diseases Clinical Research N (2025) Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections. N Engl J Med 392:1065–1078
Zhou Z, Rahme E, Abrahamowicz M, Pilote L (2005) Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 162:1016–1023